MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
77.81
-0.31
-0.40%
After Hours: 77.81 0 0.00% 16:10 12/31 EST
OPEN
77.69
PREV CLOSE
78.12
HIGH
78.82
LOW
77.37
VOLUME
929.46K
TURNOVER
--
52 WEEK HIGH
103.00
52 WEEK LOW
19.45
MARKET CAP
6.14B
P/E (TTM)
-21.6482
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KYMR last week (1222-1226)?
Weekly Report · 12/29/2025 09:55
Kymera Therapeutics Price Target Raised to $117.00/Share From $80.00 by B. Riley Securities
Dow Jones · 12/22/2025 18:29
Kymera Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 12/22/2025 18:29
B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $117
Benzinga · 12/22/2025 18:18
Kymera Therapeutics price target raised to $117 from $80 at B. Riley
TipRanks · 12/22/2025 13:55
KYMERA THERAPEUTICS INC <KYMR.O>: B. RILEY RAISES TARGET PRICE TO $117 FROM $80
Reuters · 12/22/2025 13:27
Weekly Report: what happened at KYMR last week (1215-1219)?
Weekly Report · 12/22/2025 09:55
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters · 12/22/2025 07:49
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.